Search
ublituximab (Briumvi)
Indications:
- relapsing multiple sclerosis
Contraindications:
- active hepatitis B infection
Adverse effects:
- infusion-related reactions (48%)
- headache (34%)
- nasopharyngitis (18%)
- pyrexia (14%)
- nausea (11%)
- serious infections (5%)
- 3 deaths in clinical trials
- pneumonia
- encephalitis after measles
- salpingitis after an ectopic pregnancy [1]
* no cases of progressive multifocal leukoencephalopathy reported
Mechanism of action:
- inhibits CD20
- triggers antibody-dependent cellular cytotoxicity & complement-dependent cytotoxicity leading to cell destruction.
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- George J
Anti-CD20 Agent Gains Approval for Multiple Sclerosis.
FDA greenlights ublituximab for relapsing MS.
MedPage Today December 29, 2022
https://www.medpagetoday.com/neurology/multiplesclerosis/102441
- Steinman L, Fox E, Hartung HP et al
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med 2022; 387:704-714
PMID: 36001711
https://www.nejm.org/doi/full/10.1056/NEJMoa2201904